Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

Not Applicable

Recruiting

• Conditions: Chronic Subdural Hematoma

• Registration Number: NCT06347796
• Lead Sponsor: The University of Texas Medical Branch, Galveston

Brief Summary

The goal of this clinical trial is to test in moderately symptomatic chronic subdural hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an alternative to conventional open surgery. The main questions it aims to answer are:

* Compared to open conventional surgery, does MMAE reduce the need for rescue surgery or deaths?

* What is the safety of MMAE and conventional open surgery in these patients?

Participants will be asked to:

* Share their medical history and undergo physical examinations

* Have blood drawn

* Have CT scans of the head

* Answer questionnaires

* Undergo MMAE or conventional open surgery

* Provide information about possible adverse events Researchers will compare participants in the MMAE group with those in the conventional open surgery group to see if there is a reduced need for rescue surgery or deaths and evaluate safety.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-03-22
• Study First Submitted QC: 2024-03-29
• Study First Posted: 2024-04-04
• Study Start: 2024-11-01
• Status Verified: 2025-06
• Last Update Submitted: 2025-06-28
• Last Update Posted: 2025-07-01
• Primary Completion: 2028-09
• Study Completion: 2028-09-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 520

Inclusion Criteria

1. Age 40-90 years inclusively.
2. Per CT of the head, (one of the following): Unilateral convexity CSDH measuring at least 10 mm in thickness OR Bilateral CSDH if only one side is considered for treatment and the contralateral side is asymptomatic and < 5 mm in thickness.
3. CSDH at least 2/3 isodense or hypodense, verified on axial CT slice used to measure the thickness of the qualifying CSDH.
4. Qualifying baseline head CT performed within the 7 days prior to randomization.
5. Able to undergo assigned treatment within 48 hours after randomization.
6. Patient or legally authorized representative agrees to be randomized, and provides written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.

Exclusion Criteria

1. Secondary cause apart from trauma for the qualifying SDH, such as an underlying vascular abnormality or tumor.
2. Tentorial or interhemispheric SDH.
3. Previous craniotomy for the treatment of CSDH if the craniotomy exceeds 7 cm at the maximal dimension on the baseline CT.
4. mRS of 5 or higher.
5. Emergent surgical evacuation such as open craniotomy, burr hole drainage, or Subdural Evacuating Port System (SEPS) is required for the patient.
6. Unable to withhold all antiplatelet agents or OACs for the first 7 days after randomization.
7. Indication that withdrawal of care will be implemented for the qualifying SDH.
8. Prior surgical treatment for CSDH if the surgery is less than 30 days prior to randomization.
9. On tranexamic acid.
10. Platelet count of <100,000 per microliter refractory to transfusion.
11. Coagulopathy that cannot be corrected to an INR of ≤1.5.
12. Known contraindications to angiography.
13. Known intolerance to occlusion procedures.
14. Known vascular anatomy (small artery size) or blood flow (high vascular resistance peripheral to the feeding arteries) that precludes catheter placement or embolic agent (Embosphere Microspheres or CONTOUR particles) injection.
15. Known presence of collateral vessel pathways potentially endangering normal territories or cranial nerves during embolization.
16. Known large diameter arteriovenous shunt, i.e., where the blood does not pass through an arterial/capillary/venous transition but directly from an artery to a vein or presence of patent extra-to-intracranial anastomoses (where study embolization devices could pass directly into the internal carotid artery, vertebral artery, or intracranial vasculature) that cannot be addressed with coil embolization.
17. Patient has a known active systemic infection or sepsis.
18. Patient is pregnant, planning to become pregnant, or lactating.
19. Life expectancy of less than 6 months due to comorbid terminal conditions.
20. Concurrent participation in another research protocol for investigation of an experimental therapy.
21. Known or suspected to not be able to comply with the study protocol.
22. No measurable deficit on the Timed Up and Go [TUG], Aphasia Severity Rating [ASR], or MRC.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Need for Rescue Surgery or Death	Within 180-210 days of randomization	Participants who need rescue surgery or die.

Secondary Outcome Measures

Name	Time	Method
Safety of MMAE and Conventional Open Surgery	Within 180 days of randomization.	The proportion of subjects with symptomatic ischemic stroke, serious/life threatening adverse events, worsening of neurological status (a decline of 1 point on the Markwalder scale) or development of new disabling neurological symptoms, seizures, and/or cranial neuropathy.

Trial Locations

Locations (33)

Mayo Clinic Arizona; 🇺🇸 Phoenix, Arizona, United States

Baptist Medical Center Jacksonville; 🇺🇸 Jacksonville, Florida, United States

University of Miami Miller School of Medicine; 🇺🇸 Miami, Florida, United States

University of South Florida; 🇺🇸 Tampa, Florida, United States

Emory University; 🇺🇸 Atlanta, Georgia, United States

Northwestern University; 🇺🇸 Chicago, Illinois, United States

University of Illinois; 🇺🇸 Chicago, Illinois, United States

North Shore University Health System; 🇺🇸 Evanston, Illinois, United States

University of Kansas Medical Center; 🇺🇸 Kansas City, Kansas, United States

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States

Scroll for more (23 remaining)